Vinorelbine (Navelbine)

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Disease for which it is used

• Breast cancer
• Cervical cancer
• Diffuse large B-cell lymphoma
• Esophageal cancer
• Hodgkin lymphoma
• Malignant pleural mesothelioma
• Non-small cell lung cancer
  • Non-small cell lung cancer, nonsquamous
• Ovarian cancer
• Soft tissue sarcoma
• Small cell lung cancer

Patient drug information

• Vinorelbine (Navelbine) patient drug information (Chemocare)
• Vinorelbine (Navelbine) patient drug information (UpToDate)

History of changes in FDA indication

• 12/23/1994: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC)

Also known as

• Code name: KW-2307
• Generic name: NVB, vinorelbine tartrate
• Brand names: Binorel, Biovelbin, Eunades, Flonorbin, Navelbine, Neoben, Relbovin, Vinelbine, Vinorelbel, Vinotec